Avapritinib is a selective tyrosine kinase inhibitor (TKI) that has received FDA approval for the treatment of metastatic or unresectable gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor α (PDGFRA) exon 18 mutation [269]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.